利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.024 秒)

    Fused ring heterocycles as potassium channel modulators
    1.
    发明授权
    Fused ring heterocycles as potassium channel modulators 失效
    熔融环杂环作为钾通道调节剂

    公开(公告)号：US07223768B2

    公开(公告)日：2007-05-29

    申请号：US10937958

    申请日：2004-09-10

    申请人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    发明人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    IPC分类号： A61K31/517 ,  C07D239/72

    CPC分类号： C04B35/632 ,  C07D239/92 ,  C07D285/24 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

    摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.

    摘要翻译： 提供了通过电压依赖钾通道调节钾离子通量可用于治疗疾病的化合物，组合物和方法。 更具体地，本发明提供可用于治疗中枢性或周围神经系统疾病（例如偏头痛，共济失调，帕金森病，双相情感障碍，三叉神经痛，痉挛状态，情绪障碍，脑肿瘤，精神病性障碍）的喹唑啉酮，组合物和方法 ，肌抑制，癫痫发作，癫痫，听力和视力丧失，阿尔茨海默病，年龄相关的记忆丧失，学习缺陷，焦虑和运动神经元疾病，维持膀胱控制或治疗尿失禁）和作为神经保护剂（例如，为了预防中风和 通过调节与指定条件的发作或复发相关的钾通道。

    Fused ring heterocycles as potassium channel modulators
    2.
    发明授权
    Fused ring heterocycles as potassium channel modulators 失效
    熔融环杂环作为钾通道调节剂

    公开(公告)号：US08329713B2

    公开(公告)日：2012-12-11

    申请号：US12757909

    申请日：2010-04-09

    申请人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    发明人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    IPC分类号： A61K31/517 ,  C07D239/72

    CPC分类号： C04B35/632 ,  C07D239/92 ,  C07D285/24 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

    摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.

    摘要翻译： 提供了通过电压依赖钾通道调节钾离子通量可用于治疗疾病的化合物，组合物和方法。 更具体地，本发明提供可用于治疗中枢性或周围神经系统疾病（例如偏头痛，共济失调，帕金森病，双相情感障碍，三叉神经痛，痉挛状态，情绪障碍，脑肿瘤，精神病性障碍）的喹唑啉酮，组合物和方法 ，肌抑制，癫痫发作，癫痫，听力和视力丧失，阿尔茨海默病，年龄相关的记忆丧失，学习缺陷，焦虑和运动神经元疾病，维持膀胱控制或治疗尿失禁）和作为神经保护剂（例如，为了预防中风和 通过调节与指定条件的发作或复发相关的钾通道。

    Fused ring heterocycles as potassium channel modulators
    4.
    发明授权
    Fused ring heterocycles as potassium channel modulators 失效
    熔融环杂环作为钾通道调节剂

    公开(公告)号：US07741332B2

    公开(公告)日：2010-06-22

    申请号：US11740831

    申请日：2007-04-26

    申请人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    发明人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato ,  James Barnwell Thomas, Jr.

    IPC分类号： A61K31/517 ,  C07D239/72

    CPC分类号： C04B35/632 ,  C07D239/92 ,  C07D285/24 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

    摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.

    摘要翻译： 提供了通过电压依赖钾通道调节钾离子通量可用于治疗疾病的化合物，组合物和方法。 更具体地，本发明提供可用于治疗中枢性或周围神经系统疾病（例如偏头痛，共济失调，帕金森病，双相情感障碍，三叉神经痛，痉挛状态，情绪障碍，脑肿瘤，精神病性障碍）的喹唑啉酮，组合物和方法 ，肌抑制，癫痫发作，癫痫，听力和视力丧失，阿尔茨海默病，年龄相关的记忆丧失，学习缺陷，焦虑和运动神经元疾病，维持膀胱控制或治疗尿失禁）和作为神经保护剂（例如，为了预防中风和 通过调节与指定条件的发作或复发相关的钾通道。

    Bisarylamines as potassium channel openers
    5.
    发明授权
    Bisarylamines as potassium channel openers 失效

    公开(公告)号：US06593349B2

    公开(公告)日：2003-07-15

    申请号：US10095617

    申请日：2002-03-11

    申请人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato

    发明人： Grant Andrew McNaughton-Smith ,  George Salvatore Amato

    IPC分类号： C07D40102

    CPC分类号： C07D401/12 ,  A61K31/4439 ,  C07D413/12 ,  C07D413/14

    摘要： Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides bisarylamines, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by opening potassium channels associated with the onset or recurrence of the indicated conditions.